AbbVie Cash on Hand 2010-2023 | ABBV

AbbVie cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • AbbVie cash on hand for the quarter ending December 31, 2023 was $12.816B, a 38.87% increase year-over-year.
  • AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
  • AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.
  • AbbVie cash on hand for 2021 was $9.83B, a 15.93% increase from 2020.
AbbVie Annual Cash on Hand
(Millions of US $)
2023 $12,816
2022 $9,229
2021 $9,830
2020 $8,479
2019 $39,924
2018 $8,061
2017 $9,789
2016 $6,423
2015 $8,407
2014 $8,374
2013 $9,895
2012 $7,976
2011 $653
2010 $11
2009 $
AbbVie Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $12,816
2023-09-30 $13,290
2023-06-30 $8,766
2023-03-31 $6,722
2022-12-31 $9,229
2022-09-30 $11,879
2022-06-30 $9,961
2022-03-31 $7,572
2021-12-31 $9,830
2021-09-30 $12,249
2021-06-30 $8,600
2021-03-31 $9,777
2020-12-31 $8,479
2020-09-30 $7,950
2020-06-30 $6,040
2020-03-31 $41,142
2019-12-31 $39,924
2019-09-30 $10,648
2019-06-30 $5,416
2019-03-31 $5,228
2018-12-31 $8,061
2018-09-30 $8,785
2018-06-30 $3,743
2018-03-31 $9,474
2017-12-31 $9,789
2017-09-30 $9,554
2017-06-30 $7,205
2017-03-31 $6,248
2016-12-31 $6,423
2016-09-30 $7,950
2016-06-30 $8,002
2016-03-31 $8,600
2015-12-31 $8,407
2015-09-30 $9,249
2015-06-30 $8,279
2015-03-31 $7,924
2014-12-31 $8,374
2014-09-30 $10,323
2014-06-30 $10,246
2014-03-31 $9,100
2013-12-31 $9,895
2013-09-30 $9,596
2013-06-30 $8,754
2013-03-31 $7,479
2012-12-31 $7,976
2012-09-30 $4,586
2012-06-30 $75
2012-03-31 $43
2011-12-31 $653
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $11
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $290.220B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $732.877B 105.92
Novo Nordisk (NVO) Denmark $597.021B 45.88
Johnson & Johnson (JNJ) United States $371.302B 14.75
Merck (MRK) United States $331.494B 60.31
AstraZeneca (AZN) United Kingdom $238.858B 20.76
Novartis AG (NVS) Switzerland $209.898B 14.88
Pfizer (PFE) United States $163.878B 20.37
Sanofi (SNY) $123.495B 11.65
Innoviva (INVA) United States $0.998B 7.01